Efficacy and Safety of L Arginine to Prevent Preeclampsia

Hospital Civil Juan I. Menchaca96 enrolled

Overview

Randomized double-blind controled clinical trial to assess the efficacy and safety of L-arginine to prevent preeclampsia. applied to pregnant women with risk factors for preeclampsia. the main result was the development of preeclampsia as well as side effects to taking l arginine besides perinatal outcomes

Two groups were formed. one received L arginine 3 grams orally at day from the 20th week of pregnancy. the other group received placebo. Each three weeks were evaluated in search of high blood pressure and proteinuria. The follow-up was until the end of pregnancy and two weeks after this

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Preeclampsia

Interventions

L arginineDIETARY_SUPPLEMENT

L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.

PlaceboOTHER

calcined magnesia

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * one or more risk factors for developing preeclampsia (nulliparous, previous history of preeclampsia, chronic hypertension, BMI ≥30) Exclusion Criteria: * pregnant women carriers of chronic renal failure * pre gestational diabetes * multiple pregnancy and were removed for some reason they received medication that would interfere with the interpretation of results (aspirin)

Locations (1)

Panduro Baron J Guadalupe

Guadalajara, Jalisco, Mexico

Outcomes

Primary Outcomes

efficacy of L arginine to prevent preeclampsia

number of patients with diagnosis of preeclampsia. the diagnostic was performed when they presented arterial blood pressure above 140/90 mm / Hg in the span of 6 hours and accompanied by proteinuria (\>300 milligrams in one sample) number of patients with high blood pression and proteinuria (ACOG criteria) The evaluations were performed every three weeks until week 31, then every two weeks until week 35 and weekly until pregnancy ended

Time frame: from time of randomization until the date of diagnostic of preeclampsia or two weeks after delivery wichever came first. approximalety 20 weeks.

Secondary Outcomes

perinatal outcome

number of patients with adverse perinatal outcome: APGAR scale \< 7 at five minutes, low weight for gestational age (\< 10 percentile) and CAPURRO scale \< 37 weeks also the need to enter the neonatal intensive care unit

Time frame: from time to delivery until two weeks after, approximalety 18 weeks

safety of L arginine

number of patients with adverse reactions and/or any alteration of blood test. participants are awarded a diary which recorded the symptoms that caused them any discomfort. If the discomfort was important it was reported via telephone with the treating physician. the paper was reviewed at each appointment. Blood tests such as blood count, liver function tests and kidney were performed every three weeks in search of alterations in the parameters considered normal by those tests (ACOG criteria)

Time frame: from time of randomization until birth approximalety 18 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.